An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...

Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

A new obesity drug combining four hormones may outperform Wegovy and Mounjaro. Learn what it means for health, science, and investors.

Ozempic is an FDA-approved medication for people with type 2 diabetes. It’s often prescribed off-label for weight loss — that ...

“GLP-1 drugs don’t just curb appetite – they dull the desire to drink at a metabolic level. With cravings suppressed and ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

Despite the jump in the number of teens being prescribed Wegovy, it still represents only a small fraction of kids who are living with obesity. Approximately one in 5 children and teens in the U.S.

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...